Drug intelligence / Profile preview

XL499

Development stage: Preclinical
Lead developer: Exelixis
Modality: Small Molecules

Overview

XL499 is a preclinical compound developed by Exelixis. It was the lead molecule in a program that attracted a licensing deal with Merck, which paid Exelixis an upfront fee for further development. XL499 is identified as a selective small molecule inhibitor targeting the PI3K-delta isoform of phosphoinositide 3-kinases, a pathway relevant to cancer and immune disorders. No clinical or marketed data on XL499 is available, and there are no records of XL499 having progressed beyond preclinical studies or being tested in human clinical trials[8][7].

Targets

PIK3CD (Phosphatidylinositol 3-kinase delta)

Beyond the preview

Go deeper on XL499.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on XL499.

Explore the full profile